<DOC>
	<DOCNO>NCT02826018</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics ALN-HBV healthy adult volunteer patient chronic hepatitis B virus ( HBV ) infection . In addition , study assess antiviral efficacy ALN-HBV patient HBV .</brief_summary>
	<brief_title>A Study ALN-HBV Healthy Adult Volunteers Non-cirrhotic Patients With Chronic Hepatitis B Virus ( HBV ) Infection</brief_title>
	<detailed_description>The study 3 part . Part A single ascending dose ( SAD ) study healthy volunteer . Part B single ascend dose study ( SAD ) patient HBV infection . Part C multiple ascend dose study ( MAD ) patient HBV infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>All subject : 18 65 year inclusive Women childbearing potential must negative pregnancy test , breast feeding , must willing use highly effective method contraception Agrees donate blood duration study Willing comply study requirement provide write informed consent Additional inclusion criterion patient HBV infection : Body mass index ( BMI ) â‰¥18.0 kg/m2 Must stable regimen entecavir tenofovir All subject : Any uncontrolled serious disease , medical surgical condition , may either interfere participation clinical study , and/or put subject significant risk Subjects history serious mental illness Active infection human immunodeficiency virus ( HIV ) infection , hepatitis A virus ( HAV ) , hepatitis C virus ( HCV ) infection and/or history delta virus hepatitis Known hypersensitivity contraindication medication history allergic reaction oligonucleotide Nacetylgalactosamine ( GalNAc ) Additional exclusion criterion healthy volunteer : Evidence liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Hepatitis B , Chronic</keyword>
	<keyword>Hepatitis B Infection</keyword>
	<keyword>HBV</keyword>
</DOC>